Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.69 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.69 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.69 |
| ▸ | USP2 | O75604 | 6/20 | 0.69 |
| ▸ | MMP2 | P08253 | 1/20 | 0.69 |
| ▸ | MMP3 | P08254 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 7/20 | 0.67 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.67 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL497165 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL497163 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL229272 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL8709949 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL29151798 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL8709954 | 0.99 | TDP1 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL11417262 | 0.99 | MMP2 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL8683380 | 0.99 | MMP2 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL41883 | 0.99 | MMP2 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL40834 | 0.99 | TDP1 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393512-B1 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEM CORP (JP) | 2025-10-01 | — | — | EP | disclosed |
| EP-4393512-A1 | COMPOSITION FOR MEDICINAL TABLET, MEDICINAL TABLET OBTAINED USING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Chemical Corporation (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-20240173260-A1 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-115551827-A | 9-amino-doxycycline myristoyl derivatives targeting cancer stem cells and preventing metastasis | 卢内拉生物技术有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021215405-A1 | IMMUNOSTIMULANT AND COMPOSITION FOR TREATMENT OR PREVENTION | 国立大学法人大阪大学 (JP) | 2021-10-28 | — | — | WO | disclosed |
| EP-3023109-A1 | ORALLY DISINTEGRATING TABLET | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136091-A1 | Orally Disintegrating Tablet | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| CN-105377303-A | Orally disintegrating tablet | SANWA KAGAKU KENKYUSHO CO | 2016-03-02 | — | — | CN | disclosed |
| CN-105007737-A | 3-alkyl-5-fluoro-4-substituted-imino-3, 4-dihydropyrimidin-2 (1H) -one derivatives as fungicides | DOW AGROSCIENCES LLC | 2015-10-28 | — | — | CN | disclosed |